BAER-101 is under clinical development by Baergic Bio and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BAER-101’s likelihood of approval (LoA) and phase transition for Anxiety Disorders took place on 14 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BAER-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BAER-101 overview

BAER-101 is under development for the treatment of anxiety disorders, depression, refractory epilepsy, dravet syndrome (Severe Myoclonic Epilepsy of Infancy) and fragile X syndrome. BAER-101 (AZD-7325) is a new chemical entity that is administered orally. AZD-7325 acts by targeting gamma-aminobutyric acid (GABA) receptor subunit alpha 2,3.

Quick View BAER-101 LOA Data

Report Segments
  • Innovator
Drug Name
  • BAER-101
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.